Work

Additional file 4: Figure S3. of Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Year: 2015

Type: article

Abstract: Mean (±SD) plasma concentration–time profiles of patisiran following 1 h intravenous infusion (semi-log scale) for: (a) First (Day 0) and (b) second (Day 21/28) doses. Q3W: every 3 weeks; Q4W: every 4 weeks; SD: standard deviation. (DOCX 196 kb)

Source: Figshare

DOI: 10.6084/m9.figshare.4357670

Authors: Suhr, Ole, Coelho, Teresa, Buades, Juan, Pouget, Jean, Conceicao, Isabel, Berk, John, Schmidt, Hartmut, Waddington-Cruz, Márcia, Campistol, Josep, Bettencourt, Brian, Vaishnaw, Akshay, Gollob, Jared, Adams, David

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7138339523

FWCI:

Cites:

Cited by:

Related to: 10